AstraZeneca PLC (AZN) Earnings Call Analysis

NASDAQ · Unknown · Unknown

Earnings Reports

• AstraZeneca (AZN) Q2 2026: Oncology Revenue Jumps 15% as Pipeline Diversifies Beyond LOE Headwinds
  July 27, 2026
• AstraZeneca (AZN) Q4 2025: Oncology Surges 17% as Pipeline Catalysts Drive $10B+ Peak Revenue Potential
  June 15, 2026
• AstraZeneca (AZN) Q1 2026: Oncology Surges 16% as Pipeline Readouts Set $10B+ Peak Revenue Path
  April 30, 2026
• AstraZeneca (AZN) Q3 2025: Oncology Surges 16% as $10B Pipeline Readouts Shape 2026 Trajectory
  November 11, 2025
• AstraZeneca (AZN) Q2 2025: R&D Spend Climbs to 23% of Revenue as Pipeline De-Risks $80B 2030 Target
  July 29, 2025
• AstraZeneca (AZN) Q1 2025: Broad-Based 10% Revenue Growth Anchored by Pipeline Momentum and Operational Resilience
  June 10, 2025
• AstraZeneca (AZN) Q3 2024: U.S. Investment Rises $3.5B as Global Portfolio Drives 21% Growth
  November 12, 2024
• AstraZeneca (AZN) Q2 2024: Oncology Revenue Climbs 22%, Fueling Guidance Upgrade and Pipeline Ambition
  July 25, 2024
• AstraZeneca (AZN) Q1 2024: Oncology Revenue Surges 26% as Pipeline and Portfolio Scale Drive Multi-Year Growth
  April 25, 2024
• AstraZeneca (AZN) Q4 2023: Oncology and Rare Disease Drive 21% and 12% Growth, Setting Stage for Next Decade
  February 08, 2024
• AstraZeneca (AZN) Q3 2023: Non-COVID Medicines Surge 15% as Pipeline Expansion Reshapes Growth Outlook
  November 15, 2023

Browse all companies